No connection

Search Results

ACH vs QTRX

ACH
Accendra Health, Inc.
BEARISH
Price
$2.11
Market Cap
$163.2M
Sector
Healthcare
AI Confidence
88%
QTRX
Quanterix Corporation
BEARISH
Price
$3.50
Market Cap
$164.3M
Sector
Healthcare
AI Confidence
85%

Valuation

P/E Ratio
ACH
--
QTRX
--
Forward P/E
ACH
2.25
QTRX
-1.83
P/B Ratio
ACH
-0.38
QTRX
0.55
P/S Ratio
ACH
0.02
QTRX
1.18
EV/EBITDA
ACH
4.68
QTRX
-1.16

Profitability

Gross Margin
ACH
20.78%
QTRX
46.77%
Operating Margin
ACH
8.08%
QTRX
-48.2%
Profit Margin
ACH
-12.45%
QTRX
-77.14%
ROE
ACH
-196.39%
QTRX
-34.25%
ROA
ACH
3.75%
QTRX
-13.11%

Growth

Revenue Growth
ACH
1.5%
QTRX
24.7%
Earnings Growth
ACH
--
QTRX
--

Financial Health

Debt/Equity
ACH
--
QTRX
0.13
Current Ratio
ACH
0.86
QTRX
2.84
Quick Ratio
ACH
0.1
QTRX
1.98

Dividends

Dividend Yield
ACH
--
QTRX
--
Payout Ratio
ACH
0.0%
QTRX
0.0%

AI Verdict

ACH BEARISH

The Advanced Deterministic Scorecard reveals a critically weak financial health profile with a Piotroski F-Score of just 1/9, indicating severe operational and financial distress. Despite a low forward P/E of 2.25 and a Price/Sales ratio of 0.02 suggesting apparent cheapness, negative profitability metrics—including a -12.45% profit margin and -196.39% ROE—undermine valuation appeal. The company faces acute liquidity risk with a current ratio of 0.86 and a near-zero quick ratio of 0.10, while earnings have collapsed with a YoY decline of 40.5%. Although insider sentiment is neutral and analysts project a 92% upside to a $4.08 target, the deteriorating fundamentals and lack of cash flow transparency present substantial risk.

Strengths
Low forward P/E of 2.25 may attract contrarian or value-seeking investors
Operating margin of 8.08% indicates some pricing power or cost control at operational level
Gross margin of 20.78% is relatively healthy for medical distribution sector
Risks
Piotroski F-Score of 1/9 signals extreme financial weakness and high risk of continued underperformance
Negative Price/Book of -0.38 and unreported Altman Z-Score indicate likely insolvency risk or balance sheet instability
Current and quick ratios (0.86 and 0.10) suggest imminent liquidity crisis and inability to meet short-term obligations
QTRX BEARISH

QTRX exhibits severe financial distress as evidenced by a Piotroski F-Score of 1/9, indicating critical weakness in operational efficiency and financial health. While the company maintains strong top-line revenue growth (24.7% YoY) and a healthy current ratio (2.84), these are overshadowed by a devastating profit margin of -77.14% and a consistent track record of missing earnings estimates. The stock is in a clear long-term downtrend, having lost over 94% of its value over five years, and currently trades at a significant discount to book value (P/B 0.55), suggesting a 'value trap' scenario.

Strengths
Strong YoY revenue growth of 24.70%
Low leverage with a Debt/Equity ratio of 0.13
Strong short-term liquidity (Current Ratio 2.84)
Risks
Critical operational health (Piotroski F-Score 1/9)
Deeply negative profitability (Profit Margin -77.14%)
Poor earnings reliability (Average surprise -41.54% over last 4 quarters)

Compare Another Pair

ACH vs QTRX: Head-to-Head Comparison

This page compares Accendra Health, Inc. (ACH) and Quanterix Corporation (QTRX) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.

Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.

Home
Terminal
AI
Markets
Profile